MedTrace Logo

Combination Therapy for Age-Related Macular Degeneration.

NCT00376701 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2011-09-28

No results posted yet for this study

Summary

The primary purpose of the study is to investigate whether patients with Choroidal Neovascularization secondary to Age-related Macular Degeneration, receiving triple or double therapy compared to monotherapy with Avastin will reduce the intervention rate with equivalent safety and efficacy.

Conditions

  • Age Related Macular Degeneration

Interventions

DRUG

Avastin (Bevacizumab)

Avastin 1.25 mg intravitreal

DRUG

Bevacizumab

Intravitreal 1.25 mg

DRUG

Bevacizumab

Intravitreal 1.25 mg

DRUG

Bevacizumab

Intravitreal Avastin 1.25 mg and sham reduced fluence PDT

Sponsors & Collaborators

  • QLT Inc.

    collaborator INDUSTRY

  • Canadian Retinal Trials Group

    collaborator OTHER

  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

    lead OTHER

Principal Investigators

  • Thomas G. Sheidow, MD · The University of Western Ontario

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2009-04-30
Completion
2009-04-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00376701 on ClinicalTrials.gov